The Parallax View

Home
Archive
About
A Little Gift
Biotech tracking excel of 800+ US-listed biotechs
 • 
The Parallax View

March 2022

$CRTX | Cortexyme
A post-mortem and a look at what’s next
 • 
The Parallax View

February 2022

$BNTX | BioNTech: mRNA therapies beyond the COVID-19 vaccine
An exciting approach to auto-immune conditions published in Science shows the broad potential of future mRNA therapies
 • 
The Parallax View
The State of Biotech Today
Our world in charts
 • 
The Parallax View

January 2022

The Biotech Investor's Resources
Use these to help make $XBI a better place
 • 
The Parallax View
1

December 2021

October 2021

$GLUE | Monte Rosa Therapeutics
Drugging the undruggable, not redrugging the druggable
 • 
The Parallax View
$TLIS | Talis, the Dark Horse of Point-of-Care Testing?
COVID-19 Variant & Flu POCT and the New Normal
 • 
The Parallax View
1

September 2021

CD47: Eating Up Cancer and Biobucks
8,500 words on $TRIL $ALXO $IMAB $STTK $OSE $GILD
 • 
The Parallax View

August 2021

Q2 2021 13F Review
Looking at portfolio changes for RA, Perceptive, Baker, OrbiMed, BVF, EcoR1, Redmile, Opaleye, Ghost Tree
 • 
The Parallax View
$CCCC | C4 Therapeutics
2,700 words
 • 
The Parallax View
Exclusive: $NRIX | Nurix Therapeutics
1,500 words
 • 
The Parallax View
© 2024 Substack Inc
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture